Shedrx Review: Clinical Evidence and Personalization Context

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

A Shedrx review highlights key considerations for GLP-1 users: compounded medication sourcing, transparent pricing models, and how individual metabolic factors influence treatment suitability. Many patients compare multiple platforms before selecting a GLP-1 provider, making informed evaluation essential.

What matters most is understanding your own metabolic context and how different GLP-1 compounds may fit your clinical picture. PlexusDx emphasizes precision wellness through genetic insights and licensed 503A compounding, allowing providers to tailor recommendations based on your specific peptide pathway predispositions.

Compounded vs. Branded GLP-1 Medications: What Patients Should Know

GLP-1 medications exist in two primary forms: branded pharmaceuticals (Ozempic, Wegovy, Mounjaro) manufactured by large pharma, and compounded versions created in licensed 503A pharmacies. Both carry regulatory oversight, but sourcing, cost, and availability differ significantly between these pathways.

Compounded GLP-1 medications offer flexibility and often lower costs, but require prescriptions from licensed providers and careful pharmacy verification. Understanding the difference between 503A compounding (patient-specific, smaller batches) and 503B manufacturing (larger sterile operations) helps patients evaluate safety and quality standards accurately.

Pricing Models and Transparent Cost Structures

GLP-1 platforms vary widely in pricing, from subscription models to à la carte consultations plus medication fees. A Shedrx review typically emphasizes cost clarity—knowing whether genetic testing, provider fees, and shipping are included or additional helps patients budget accurately.

PlexusDx pricing includes compounded semaglutide at $189/mo month-to-month, or from $149/mo on the 6-month plan, tirzepatide $289/mo month-to-month, or from $249/mo on the 6-month plan, and genetic testing at $298. Transparent pricing allows patients to compare total cost of care across multiple providers fairly.

Service Component	Typical Cost Range	What It Includes
Compounded Semaglutide (monthly)	$189	Medication only, 4-week supply from 503A pharmacy
Compounded Tirzepatide (monthly)	$289	Medication only, 4-week supply from 503A pharmacy
Precision Peptide Genetic Test	$298	Predisposition analysis in GIPR, FTO, MC4R pathways; standalone or add-on
Provider Consultation	Included/varies	Initial intake, dose escalation guidance, safety monitoring

Genetic Predispositions and Personalized Medication Selection

Individual variation in GLP-1 response partly reflects genetic predispositions in peptide receptor pathways. Variants in GIPR, FTO, and MC4R genes can influence metabolic efficiency, appetite signaling, and medication effectiveness. Genetic testing may provide useful context for provider conversations.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to GLP-1 medications or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Safety, Eligibility, and Provider-Led Decision Making

GLP-1 medications are prescription drugs requiring medical evaluation for contraindications, such as personal or family history of medullary thyroid cancer, pancreatitis, or severe gastrointestinal disease. Any review of GLP-1 providers should confirm they conduct thorough health screening before prescribing.

A qualified provider should discuss your full medical history, current medications, metabolic markers, and treatment goals before recommending a specific compound or dose. Genetic test results should be interpreted within this clinical context—they provide predisposition insights, not medical advice or guarantees of outcome.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic testing may help provide context about your individual peptide pathway predispositions—specifically GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 variants. This information can support a more informed conversation with your provider about whether compounded semaglutide, tirzepatide, or other GLP-1 options align with your metabolic profile.

The Precision Peptide Genetic Test does not predict exact medication response or guarantee outcome. Instead, it reveals predispositions that may influence how your body processes GLP-1 compounds and manages appetite regulation. Combined with your clinical history, biomarkers, and provider assessment, this knowledge supports personalized decision-making.

Understanding your genetic context alongside transparent pricing, verified 503A pharmacy sourcing, and qualified provider oversight creates a complete picture. PlexusDx integrates these elements to help patients evaluate GLP-1 options with their healthcare team, moving beyond generic marketing toward precision wellness.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How does Shedrx's business model compare to other GLP-1 platforms?

Shedrx operates a telehealth-to-pharmacy model with subscription billing. PlexusDx similarly connects patients to licensed providers and 503A compounding, but emphasizes genetic testing and transparent flat per-compound pricing to support personalized provider conversations rather than algorithmic matching.

What is the difference between 503A compounded and branded GLP-1 medications?

Branded medications (Ozempic, Wegovy) are mass-manufactured by pharmaceutical companies. Compounded versions are prepared in licensed 503A pharmacies per individual prescriptions. Both require provider oversight, but compounding offers cost flexibility and sourcing transparency.

How much do PlexusDx compounded GLP-1 medications cost?

PlexusDx compounded semaglutide ranges $189/mo month-to-month, or from $149/mo on the 6-month plan, tirzepatide $289/mo month-to-month, or from $249/mo on the 6-month plan. The Precision Peptide Genetic Test is $298. Pricing includes medication and basic provider support; insurance coverage varies by plan.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Genetic testing reveals predispositions in peptide pathways (GIPR, FTO, MC4R), which may provide context for personalized treatment. However, genetics alone does not predict exact medication response—clinical history, biomarkers, and provider assessment are equally important for informed decision-making.

Who should not use GLP-1 medications like those offered through platforms like Shedrx?

GLP-1 is contraindicated in patients with personal or family history of medullary thyroid cancer, pancreatitis, or severe gastrointestinal disease. Pregnancy, severe kidney disease, and certain medications also require provider evaluation. Always disclose your complete medical history before starting any GLP-1 therapy.

Related Reading

• Zepbound Review
• Liraglutide Review
• Victoza Review
• Tirzepatide Review

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.